110,99 €
inkl. MwSt.
Versandkostenfrei*Erscheint vorauss. 1. Juni 2025
Melden Sie sich
hier
hier
für den Produktalarm an, um über die Verfügbarkeit des Produkts informiert zu werden.
55 °P sammeln
Andere Kunden interessierten sich auch für
![The 14 Day Rule and Human Embryo Research]( "The 14 Day Rule and Human Embryo Research")
The 14 Day Rule and Human Embryo Research184,99 €![Neurogenetic Diagnoses]( "Neurogenetic Diagnoses")
Neurogenetic Diagnoses182,99 €![Environments, Risks and Health]( "Environments, Risks and Health")
Environments, Risks and Health198,99 €![The Opioid Fix]( "The Opioid Fix")
The Opioid Fix23,99 €![The Disability Bioethics Reader]( "The Disability Bioethics Reader")
The Disability Bioethics Reader175,99 €![New Life Courses, Social Risks and Social Policy in East Asia]( "New Life Courses, Social Risks and Social Policy in East Asia")
New Life Courses, Social Risks and Social Policy in East Asia209,99 €![The Politics of the Pharmaceutical Industry and Access to Medicines]( "The Politics of the Pharmaceutical Industry and Access to Medicines")
The Politics of the Pharmaceutical Industry and Access to Medicines198,99 €
Controlling Pharmaceutical Risks analyses changes in drug testing since the late 1990s, specifically geneticization of carcinogenic risk assessment and regulation of pharmaceuticals, involving issues fundamental to bio-science, medical treatment and patients' health, such as what knowledge is judged necessary to determine carcinogenic risk to humans, and how that judgement transpired.